Fig. 1 · Structure

Documents & Downloads

Risedronate sodium

Cat. No. A10796 CAS 115436-72-1
Risedronate sodium is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Risedronate sodium Research Summary

This section summarizes 2 in vivo studies of Risedronate sodium from 1 published reference. In vivo models include OVX-induced osteoporotic ddY mice.

Risedronate sodium In Vivo Studies

In studies using OVX-induced osteoporotic ddY mice, Risedronate sodium was administered at 2.5mg/kg once daily for 28 days, with OVX controls for comparison. Reported trabecular bone volume was 35.71 ± 5.63%. Reported osteoclast cell number was 19.00 ± 2.93 N/epiphyseal. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Trabecular Bone Volume in OVX-Induced Osteoporotic Mice

Animal study · OVX-induced osteoporotic ddY mice [1]

OVX-induced osteoporotic ddY mice received Risedronate sodium at 2.5mg/kg once daily for 28 days, with an OVX control for comparison. Trabecular bone volume was 35.71 ± 5.63%.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Trabecular bone volume (%)Tibia BV/TV 35.71 ± 5.63%[1]

Conditions shared by the study groups

Treatment course
once daily for 28 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Risedronate sodium 2.5mg/kgOVX35.71 ± 5.63%[1]
Risedronate sodium 2.5mg/kg
Model: OVX-induced osteoporotic ddY mice
Reported limits: Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Risedronate sodium; Compound label in the paper: Risedronate

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Effect of Nox inhibitor on OVX-induced osteoporosis (S44); Methods > Histomorphometrical analysis (S113); Figure 5 legend (S174); Table 1 legend (S192); Table 1 (T1.h2, T1.r3, T1.r4)

Trabecular bone volume (%): Trabecular bone volume (%); comparator: OVX — Table 1 legend (S192); Table 1 (T1.h2, T1.r4)

Risedronate sodium 2.5mg/kg · Methods > Histomorphometrical analysis (S113); Table 1 legend (S192); Table 1 (T1.h2, T1.r4)

Osteoclast Cell Number in OVX-Induced Osteoporotic Mice

Animal study · OVX-induced osteoporotic ddY mice [1]

OVX-induced osteoporotic ddY mice received Risedronate sodium at 2.5mg/kg once daily for 28 days, with an OVX control for comparison. Osteoclast cell number was 19.00 ± 2.93 N/epiphyseal.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Osteoclast cell number (N/epiphyseal)Femur N.OC/BS 19.00 ± 2.93[1]

Conditions shared by the study groups

Treatment course
once daily for 28 days
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Risedronate sodium 2.5mg/kgOVX19.00 ± 2.93[1]
Risedronate sodium 2.5mg/kg
Model: OVX-induced osteoporotic ddY mice
Reported limits: Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Risedronate sodium; Compound label in the paper: Risedronate

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Effect of Nox inhibitor on OVX-induced osteoporosis (S44); Methods > Histomorphometrical analysis (S113); Figure 5 legend (S174); Table 2 legend (S194); Table 2 (T2.h2, T2.r3, T2.r4)

Osteoclast cell number (N/epiphyseal): Osteoclast cell number (N/epiphyseal); comparator: OVX — Table 2 legend (S194); Table 2 (T2.h2, T2.r4)

Risedronate sodium 2.5mg/kg · Methods > Histomorphometrical analysis (S113); Table 2 legend (S194); Table 2 (T2.h2, T2.r4)

Specifications

Manufacturer Adooq Bioscience
CAS Number 115436-72-1
Formula C7H10NNaO7P2
Molecular Weight 305.09
Synonyms Actonel
SMILES
C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)[O-].[Na+]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water 2 mg/mL (6.55 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Risedronate sodium Research References

  1. [1] Joo JH, Huh JE, Lee JH, et al. A novel pyrazole derivative protects from ovariectomy-induced osteoporosis through the inhibition of NADPH oxidase. Sci Rep (2016). PMID: 26975635 DOI: 10.1038/srep22389 Source material

Added to your cart

View Cart Checkout
Loading...